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ABSTRACT 
 
 
Morphine can delay absorption of P2Y12-inhibitors in ST-elevation myocardial infarction 
(STEMI) patients, which has the potential to expose these patients to increased stent 
thrombosis risk after primary percutaneous coronary intervention (PPCI). Limited evidence 
exists for pharmacotherapeutic strategies aiming to mitigate this risk. We evaluated the impact 
of guideline-driven ‘routine’ glycoprotein IIb/IIIa antagonist (GPI) use in morphine-treated 
patients undergoing PPCI. 3224 consecutive STEMI patients undergoing PPCI at a large 
tertiary cardiac centre between 2012 and 2017 were evaluated. GPI use and outcomes before 
and after introduction of a local guideline were compared, and rates of definite stent thrombosis 
were identified at 24 hours and 30 days. GPI use increased from 42.4% to 69.9% after the 
introduction of the new guideline. Stent thrombosis occurred in 1.3% (26/1947) pre-guideline 
and 0.6% (7/1244) post-guideline (P = 0.037). Of the 33 stent thrombosis cases, 90% (27/30) 
had received morphine, of whom 85.2% (23/27) had not received adjunctive GPI. Complete 
records for assessing 30-day bleeding rates were only available in 374 patients and, in this 
subset, there was no significant difference in rates of GUSTO moderate or severe bleeding 
before vs. after introduction of the local guideline (1.7% vs 2.8%; P = 0.47) although, in both 
cohorts combined, any GUSTO bleeding was observed more frequently in GPI-treated patients 
(21.8%) compared to those not receiving a GPI (10.0%; P = 0.002). In conclusion, routine GPI 
use in morphine-treated STEMI patients undergoing PPCI appears to protect against stent 
thrombosis. Large-scale studies are needed to establish the overall risk-benefit of GPI therapy 
in morphine-treated PPCI patients and to assess alternative strategies for preventing acute stent 
thrombosis in these patients. 
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ABBREVIATIONS LIST 
 
 
 
 
ACS  Acute coronary syndrome 
DAPT  Dual Antiplatelet Therapy  
GPI  Glycoprotein IIb/IIIa antagonist 
GUSTO Global Utilization of Streptokinase and tPA for Occluded arteries  
PPCI  Primary Percutaneous Coronary Intervention 
STEMI ST-elevation myocardial infarction 
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INTRODUCTION 
 
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is the standard of care for 
the management of acute coronary syndromes (ACS) and for percutaneous coronary 
intervention (PCI), being recommended in the current international guidelines.
1,2,3,4
 In the 
setting of ST-elevation myocardial infarction (STEMI) and other ACS manifestations, the 
P2Y12 inhibitors ticagrelor and prasugrel are now preferred to clopidogrel as first-line therapy 
in those without contraindications, except in those requiring oral anticoagulant therapy.
1,24
 
Morphine is often used in patients with STEMI for analgesia, sedation, anxiolysis and 
reduction of adrenergic drive, heart rate and myocardial oxygen consumption.
1,2,5
 However, 
morphine has been shown to delay absorption of P2Y12-inhibitors in STEMI patients, which 
has the potential to expose these patients to increased thrombotic risk.
6,7,8,9
 Some evidence of a 
harmful effect comes from the ATLANTIC (Administration of Ticagrelor in the Cath Lab or in 
the Ambulance for New ST Elevation Myocardial Infarction to Open the Coronary Artery) 
study, which showed a significant interaction between morphine use and the effects of pre-
hospital administration of ticagrelor; pre-hospital compared to in-hospital ticagrelor 
administration appeared to improve resolution of ST-elevation in those who did not receive 
morphine whereas no apparent benefit was seen in morphine-treated patients.
10
 Another study 
found that morphine-treated STEMI patients exhibited larger infarct size and lower 
myocardial salvage index
11
, although a further observational study found no differences in in-
hospital complications or 1-year mortality.
12
 Evidence for clinical efficacy of GPI use in 
morphine-treated patients with STEMI is limited. In a small observational study (32 STEMI 
patients treated with prasugrel), a bridging strategy with abciximab in morphine-treated 
patients appeared to ensure adequate platelet inhibition as measured with Multiplate electrode 
aggregometry.
13
 However, no evidence is available regarding clinical outcomes with such a 
strategy and no data exist about the effect in ticagrelor-treated patients in this setting. The 
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recommendations for GPI use in addition to P2Y12 inhibitors in the current guidelines are 
restricted to specific situations (bail-out strategy, no-reflow or angiographic evidence of a large 
thrombus).
24
 No specific recommendations are given for morphine-treated patients. Although 
the aforementioned studies suggest that platelet function and clinical outcomes are worse in 
morphine-treated STEMI patients, no accepted strategies exist to overcome this issue. 
Therefore, an institutional guideline was introduced in our hospital in 2012 with the purpose of 
improving the outcomes of morphine-treated STEMI patients. 
 
The aim of the current observational cohort study was to compare the effect of GPI before and 
after the introduction of this guideline for morphine-treated STEMI patients in terms of stent 
thrombosis and mortality, as well as to obtain pilot data on bleeding events. 
 
 
METHODS 
Consecutive patients undergoing primary PCI for STEMI at South Yorkshire Cardiothoracic 
Centre, Sheffield, United Kingdom, between 1 April 2012 and 28 February 2017 were 
included. This hospital provides a primary PCI service for the surrounding population of 
approximately 1.8 million people. Standard antithrombotic therapy throughout the observation 
period consisted of aspirin and ticagrelor (or prasugrel if ticagrelor was not tolerated or 
cautioned for reasons other than bleeding risk). Heparin was given intravenously or intra-
arterially at a dose of approximately 70 units/kilogram. Use of GPI in morphine-treated 
patients was encouraged after introduction of the local protocol in March 2015, which 
specifically recommended that “in the absence of contraindication, tirofiban should be 
considered routinely in patients who have received morphine prior to or shortly after loading 
dose of P2Y12 inhibitor” at an intravenous bolus dose of tirofiban 25 mcg/kg followed by 
maintenance dose of 0.15 mcg/kg/min for a duration of 6 hours, unless a reduced dose was 
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indicated for renal failure or longer duration was indicated for management of residual 
thrombus.  
GPI use as documented in the procedure information system was collected and compared 
between the pre-guideline group (April 2012 to February 2015) and the post-guideline group 
(from March 2015 to February 2017).  
A search was performed for patients undergoing a re-PCI within 30 days and PCI reports were 
reviewed to identify any possible cases of stent thrombosis. Cases that met the Academic 
Research Consortium criteria for definite stent thrombosis
14
 were recorded and additional 
details regarding morphine were collected for these patients. 30-day vital status was available 
for all patients from the national register of deaths. 
 
Bleeding rates in local cohort 
Bleeding rates and details of in-ambulance morphine use were not available for many patients, 
partly due to transfer to local hospitals after 12 hours, meaning that complete hospital records 
were not available, or due to incomplete records of the in-ambulance treatment. Consequently, 
a detailed analysis was performed in a sub-cohort of 374 local STEMI patients in order to 
provide pilot data on bleeding rates, according to Global Utilization of Streptokinase and tPA 
for Occluded arteries (GUSTO) criteria for mild, moderate and severe bleeding, in the first 30 
days. Bleeding rates were compared between the pre-guideline cohort and the post-guideline 
cohort, between GPI-treated patients and patients not treated with GPI, and, finally, in patients 
who received the institutional “guideline-based therapy” (i.e. morphine-treated patients who 
received GPI or patients who did not receive morphine and did not receive GPI) versus patients 
not receiving the institutional guideline-based therapy. Patients were excluded if they were 
transferred after PCI to their local district general hospital. For the bleeding outcomes, only 
procedures performed by operators using predominantly radial access at the beginning of the 
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census date (1 April 2012) were included in order to reduce bias from increased adoption of, 
and skill in using, radial artery access during the second period leading to reduced bleeding 
risk.
1-2, 15
 
 
Statistical analysis 
Categorical variables were summarized by frequencies and percentages and Chi-square tests 
were used in intergroup comparisons of categorical variables. Fisher’s Exact Test was used for 
low frequency events. Continuous variables were summarized as mean and standard deviation, 
and values were compared using a standard t-test for normally distributed data. Stent 
thrombosis rates were compared with Kaplan Meier plots using log ranks test. The primary 
outcome was definite stent thrombosis at 30 days and secondary outcomes were definite stent 
thrombosis at 24 hours and all-cause mortality at 30 days. 
 
 
RESULTS 
Study population 
3224 consecutive STEMI patients undergoing primary PCI were included. Details of repeat 
PCI procedures and all-cause deaths within 24 hours and at 30 days were available for all these 
patients. In the post-guideline cohort, radial access was more common, and patients presented 
more frequently with cardiogenic shock, whereas peripheral arterial disease was less common 
(Table 1). Details regarding GPI use were available in 2297/3224 (71.2%) of patients. GPI use 
increased from 42.4% to 69.9% after the introduction of the new guideline (Table 2). 
 
Outcomes 
85 of 3224 patients underwent re-PCI within 30 days, in whom 33 cases of definite stent 
thrombosis were identified (1.0%). 26 stent thrombosis events occurred in the cohort before the 
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introduction of the guideline (26/1973; 1.3%) compared with 7 stent thrombosis events 
(7/1251; 0.6%) occurring after the introduction of the new guideline (p=0.037, log-rank 
test)(Figure 1A). The majority of stent thrombosis events (29/33) were acute (i.e. occurring 
within 24 hours) with fewer events post-guideline compared with pre-guideline (P = 0.037, 
log-rank test)(Figure 1B). For 30 out of 33 stent thrombosis patients, details on morphine use 
were available: 27/30 (90%) patients had received morphine, of whom 23/27 (85.2%) had not 
received adjunctive GPI. No significant difference in 30-day mortality was observed between 
the pre- and post-guideline group (5.9% vs. 7.3%, p=0.13). 
When stratified for GPI use rather than time period, 5/1217 (0.4%) of patients receiving GPI 
suffered a stent thrombosis vs. 28/1080 (2.6%, p<0.0001) of patients who did not receive GPI 
(Table 3).  
 
Bleeding rates in local subgroup 
2387 patients were transferred back to their local hospital following their primary PCI 
procedure. Of the remaining 937 patients, a total of 374 patients were included in the bleeding 
analysis (Figure 2). Details regarding GPI use were available in all patients and details 
regarding morphine use were available in 363 of 374 patients (97.1%). Baseline characteristics 
were similar to the overall cohort (Table 1). Following introduction of the institutional 
guideline, GPI use increased from 42.9% to 66.4%. Any GUSTO bleeding occurred in 17.6% 
of patients pre-guideline and 13.5% of patients post-guideline (p=0.29) and GUSTO moderate 
or severe bleeding occurred in 1.7% and 2.8%, respectively (p=0.47). 
In GPI-treated patients during either time period, any GUSTO bleeding was more frequently 
observed compared with patients not treated with GPI (21.8% vs. 10.0%, respectively; 
p=0.002) but differences in GUSTO moderate or severe bleeding were numerically but not 
statistically significant (3.1% vs. 1.1%; p=0.29). Despite the aim of limiting differences in 
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radial access use between the two time periods, there was an increase in use of radial access in 
the post-guideline period (Table 1). 
 
DISCUSSION  
The introduction of a new guideline in our centre has led to a 65% relative increase of GPI use 
in patients with STEMI undergoing primary PCI. There was a significant decrease in the 
number of definite stent thrombosis cases after the introduction of the new guideline. Overall, a 
significantly lower incidence of stent thrombosis was observed in GPI-treated patients. The 
majority of patients suffering a stent thrombosis had received morphine but not adjunctive GPI. 
More bleeding events were observed with GPI use but there was not a statistically significant 
increase in moderate-to-severe GUSTO bleeding. The increased risk of major bleeding with 
GPI is well documented and consequently this strategy may not be the optimal means of 
preventing acute stent thrombosis in morphine-treated primary PCI patients. Indeed, we have 
recently conducted a pharmacodynamic study to assess the impact of a bolus and 6-hour 
infusion of enoxaparin in primary PCI patients as an alternative strategy to routine use of GPI 
in morphine-treated patients and are currently comparing this against a strategy of routine use 
of tirofiban with unfractionated heparin (NCT03568838)
16
. Cangrelor is a rational option for 
providing parenteral P2Y12 inhibition pending the absorption of an oral P2Y12 inhibitor 
although a standard 2-hour cangrelor infusion may not be sufficient to cover the period of 
delayed absorption of the oral inhibitor in all patients and care must be taken if clopidogrel or 
prasugrel is used as the oral inhibitor since cangrelor can block the binding of clopidogrel and 
prasugrel active metabolites to the P2Y12 receptor.
17, 18
  
 
This observational study is the first to describe the feasibility and outcomes of ‘routine’ GPI 
use in morphine-treated patients undergoing primary PCI. Overall, the adherence to the 
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protocol was fair. Whereas the use of GPI has substantially increased after the introduction of 
the new guideline, still not all morphine-treated patients received adjunctive GPI. This could in 
part be explained by other factors playing a role in clinical practice, such as patient bleeding 
risk and possible contra-indications. Equally, other patients received GPI without being treated 
with morphine, thus a reflection of other perceived indications for GPI use, such as residual 
thrombus load after PCI.  
 
Limitations 
The observational and retrospective nature of this registry, evaluating the effects of the 
introduction a new local guideline, implies that treatment strategy was not randomised. Patients 
were not followed up prospectively and so we cannot be certain that events were not missed. 
However, since our hospital is the only one providing a PCI service to the surrounding 
population, we considered that re-PCI rates for non-fatal stent thrombosis at our centre are a 
reasonable reflection of the impact of a change in protocol on event rates. 
Details of morphine use were only available in a sub-cohort of patients, which meant that the 
study was not designed to explore the effect of morphine on stent thrombosis risk. 
Consequently, the observation of a high rate of morphine use (90%) in the stent thrombosis 
patients is subject to bias and can only be viewed as hypothesis-generating.  
A further limitation is that details on bleeding outcomes were only available in a local sub-
cohort that was relatively small since a substantial number of patients had been excluded, 
mostly due to repatriation within 12-24 hours of patients to district general hospitals following 
primary PCI, and so our analyses are not sufficient to evaluate the safety of increased use of 
GPI. Selection on the basis of geography is unlikely to alter the finding of this registry other 
than to reduce the sample size. However, the unavailability of a large number of complete 
records may have biased the findings and further prospective studies are required for more 
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reliable assessment of bleeding rates. The increased use of radial artery access may have 
attenuated the effect of increased GPI use on bleeding events. As such, the bleeding data are 
intended only to provide crude pilot data for planning such studies and also do not provide any 
guide to the safety of increased GPI use when femoral artery access is used.  
Finally, over time between the two observation periods, procedural techniques might have 
changed. Although adjustment for possible confounding variables was not possible, we assume 
that changes in procedural techniques were limited, as the total time period (<5 years) of this 
registry was relatively small. Moreover, as illustrated in Table 1, no major differences with 
regard to baseline clinical and procedural characteristics were observed between the two 
cohorts other than an increased use of radial artery access. 
 
CONCLUSIONS 
This observational study is the first to describe the feasibility and outcomes of ‘routine’ GPI 
use in morphine-treated patients undergoing primary PCI. Our results suggest that GPI use is 
highly protective for the occurrence of acute stent thrombosis. Further large-scale registries and 
clinical trials are needed to further establish the overall risk-benefit of GPI therapy in 
morphine-treated STEMI patients and to assess alternative strategies for preventing acute stent 
thrombosis in morphine-treated patients. 
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FIGURES 
 
 
Figure 1 Rates of definite stent thrombosis pre- and post-introduction of local guideline   
 
 
Figure 2 Flow Chart of Patient Selection 
 
  Legend: 
PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial 
infarction; STE, ST elevation 
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Figure 2 
 
 
